시장보고서
상품코드
1283912

세계의 항응고제 시장(2023-2027년)

Global Anticoagulants Market 2023-2027

발행일: | 리서치사: TechNavio | 페이지 정보: 영문 171 Pages | 배송안내 : 즉시배송


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

항응고제 시장은 2022-2027년 180억 9,194만 달러, 예측 기간 중 CAGR은 8.42%로 예측됩니다.

항응고제 시장에 관한 전체적인 분석, 시장 규모와 예측, 동향, 성장 촉진요인·과제 및 약 25개 벤더를 다룬 벤더 분석 등을 제공합니다.

현재 시장 시나리오, 최신 동향과 촉진요인, 시장 전체의 환경에 관한 최신 분석을 제공하고 있습니다. 시장은 신규 경구약의 도입, 응고 장애의 유병률 증가, 고관절 및 슬관절 수술의 증가에 의해 촉진되고 있습니다.

본 조사에서는 항응고제 해독제의 등장이 향후 수년간 항응고제 시장의 성장을 촉진하는 주요 이유의 하나로 식별하고 있습니다. 또한 환자 지원 프로그램이나 신흥 국가에 대한 관심의 증가는 시장의 큰 수요로 연결될 전망입니다.

목차

제1장 주요 요약

  • 시장 개요

제2장 시장 구도

  • 시장 에코시스템

제3장 시장 규모

  • 시장의 정의
  • 시장 부문 분석
  • 시장 규모 2022
  • 시장 전망 2022-2027

제4장 시장 규모 실적

  • 세계의 항응고제 시장 2017-2021
  • 투여 경로 부문 분석 2017-2021
  • 유형 부문 분석 2017-2021
  • 지역별 부문 분석 2017-2021
  • 국가별 부문 분석 2017-2021

제5장 Five forces 분석

  • Five Forces 요약
  • 구매자의 교섭력
  • 공급 기업의 교섭력
  • 신규 진출업체의 위협
  • 대체품의 위협
  • 경쟁의 위협
  • 시장 현황

제6장 시장 세분화 : 투여 경로별

  • 시장 부문
  • 비교 : 투여 경로별
  • 경구 항응고제 : 시장 규모와 예측 2022-2027
  • 주입 가능한 항응고제 : 시장 규모와 예측 2022-2027
  • 시장 기회 : 투여 경로별

제7장 시장 세분화 : 유형별

  • 시장 부문
  • 비교 : 유형별
  • 제Xa 인자 저해제 : 시장 규모와 예측 2022-2027
  • DTI : 시장 규모와 예측 2022-2027
  • 헤파린 : 시장 규모와 예측 2022-2027
  • 비타민 K 길항제 : 시장 규모와 예측 2022-2027
  • 시장 기회 : 유형별

제8장 고객 상황

  • 고객 상황의 개요

제9장 지역별 상황

  • 지역별 세분화
  • 지역별 비교
  • 북미 : 시장 규모와 예측 2022-2027
  • 유럽 : 시장 규모와 예측 2022-2027
  • 아시아 : 시장 규모와 예측 2022-2027
  • 세계의 기타 지역 : 시장 규모와 예측 2022-2027
  • 미국 : 시장 규모와 예측 2022-2027
  • 독일 : 시장 규모와 예측 2022-2027
  • 영국 : 시장 규모와 예측 2022-2027
  • 일본 : 시장 규모와 예측 2022-2027
  • 캐나다 : 시장 규모와 예측 2022-2027
  • 지역 상황별 시장 기회

제10장 촉진요인, 과제 및 동향

  • 시장 촉진요인
  • 시장이 해결해야 할 과제
  • 촉진요인과 과제의 영향
  • 시장 동향

제11장 벤더 구도

  • 개요
  • 벤더 구도
  • 혼란의 상황
  • 업계의 리스크

제12장 벤더 분석

  • 대상 벤더
  • 벤더의 시장 포지셔닝
  • Abbott Laboratories
  • Aspen Pharmacare Holdings Ltd
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • Dr Reddys Laboratories Ltd.
  • GlaxoSmithKline Plc
  • Johnson and Johnson Services Inc.
  • LEO Pharma AS
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

제13장 부록

KSA 23.06.08

The anticoagulants market is forecasted to grow by USD 18,091.94 mn during 2022-2027, accelerating at a CAGR of 8.42% during the forecast period. The report on the anticoagulants market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by introduction of novel oral anticoagulants, growing prevalence of coagulation disorders, and increase in hip and knee surgeries.

Technavio's anticoagulants market is segmented as below:

By Administration

  • Oral anticoagulants
  • Injectable anticoagulants

By Type

  • Factor Xa inhibitors
  • DTIs
  • Heparin
  • Vitamin K antagonists

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the advent of anticoagulant antidotes as one of the prime reasons driving the anticoagulants market growth during the next few years. Also, patient assistance programs and increasing focus toward emerging economies will lead to sizable demand in the market.

The report on the anticoagulants market covers the following areas:

  • Anticoagulants market sizing
  • Anticoagulants market forecast
  • Anticoagulants market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anticoagulants market vendors that include Abbott Laboratories, Amphastar Pharmaceuticals Inc., Aspen Pharmacare Holdings Ltd, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Laboratorios Farmaceuticos ROVI S A, LEO Pharma AS, Novartis AG, Pfizer Inc., Sanofi SA, Shenzhen Hepalink Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and United Therapeutics Corp.. Also, the anticoagulants market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027
  • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global anticoagulants market 2017 - 2021
  • Exhibit 18: Historic Market Size - Data Table on global anticoagulants market 2017 - 2021 ($ million)
  • 4.2 Route of Administration Segment Analysis 2017 - 2021
  • Exhibit 19: Historic Market Size - Route of Administration Segment 2017 - 2021 ($ million)
  • 4.3 Type Segment Analysis 2017 - 2021
  • Exhibit 20: Historic Market Size - Type Segment 2017 - 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 - 2021
  • Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 - 2021
  • Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Route of Administration

  • 6.1 Market segments
  • Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
  • Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)
  • 6.2 Comparison by Route of Administration
  • Exhibit 32: Chart on Comparison by Route of Administration
  • Exhibit 33: Data Table on Comparison by Route of Administration
  • 6.3 Oral anticoagulants - Market size and forecast 2022-2027
  • Exhibit 34: Chart on Oral anticoagulants - Market size and forecast 2022-2027 ($ million)
  • Exhibit 35: Data Table on Oral anticoagulants - Market size and forecast 2022-2027 ($ million)
  • Exhibit 36: Chart on Oral anticoagulants - Year-over-year growth 2022-2027 (%)
  • Exhibit 37: Data Table on Oral anticoagulants - Year-over-year growth 2022-2027 (%)
  • 6.4 Injectable anticoagulants - Market size and forecast 2022-2027
  • Exhibit 38: Chart on Injectable anticoagulants - Market size and forecast 2022-2027 ($ million)
  • Exhibit 39: Data Table on Injectable anticoagulants - Market size and forecast 2022-2027 ($ million)
  • Exhibit 40: Chart on Injectable anticoagulants - Year-over-year growth 2022-2027 (%)
  • Exhibit 41: Data Table on Injectable anticoagulants - Year-over-year growth 2022-2027 (%)
  • 6.5 Market opportunity by Route of Administration
  • Exhibit 42: Market opportunity by Route of Administration ($ million)
  • Exhibit 43: Data Table on Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Type

  • 7.1 Market segments
  • Exhibit 44: Chart on Type - Market share 2022-2027 (%)
  • Exhibit 45: Data Table on Type - Market share 2022-2027 (%)
  • 7.2 Comparison by Type
  • Exhibit 46: Chart on Comparison by Type
  • Exhibit 47: Data Table on Comparison by Type
  • 7.3 Factor Xa inhibitors - Market size and forecast 2022-2027
  • Exhibit 48: Chart on Factor Xa inhibitors - Market size and forecast 2022-2027 ($ million)
  • Exhibit 49: Data Table on Factor Xa inhibitors - Market size and forecast 2022-2027 ($ million)
  • Exhibit 50: Chart on Factor Xa inhibitors - Year-over-year growth 2022-2027 (%)
  • Exhibit 51: Data Table on Factor Xa inhibitors - Year-over-year growth 2022-2027 (%)
  • 7.4 DTIs - Market size and forecast 2022-2027
  • Exhibit 52: Chart on DTIs - Market size and forecast 2022-2027 ($ million)
  • Exhibit 53: Data Table on DTIs - Market size and forecast 2022-2027 ($ million)
  • Exhibit 54: Chart on DTIs - Year-over-year growth 2022-2027 (%)
  • Exhibit 55: Data Table on DTIs - Year-over-year growth 2022-2027 (%)
  • 7.5 Heparin - Market size and forecast 2022-2027
  • Exhibit 56: Chart on Heparin - Market size and forecast 2022-2027 ($ million)
  • Exhibit 57: Data Table on Heparin - Market size and forecast 2022-2027 ($ million)
  • Exhibit 58: Chart on Heparin - Year-over-year growth 2022-2027 (%)
  • Exhibit 59: Data Table on Heparin - Year-over-year growth 2022-2027 (%)
  • 7.6 Vitamin K antagonists - Market size and forecast 2022-2027
  • Exhibit 60: Chart on Vitamin K antagonists - Market size and forecast 2022-2027 ($ million)
  • Exhibit 61: Data Table on Vitamin K antagonists - Market size and forecast 2022-2027 ($ million)
  • Exhibit 62: Chart on Vitamin K antagonists - Year-over-year growth 2022-2027 (%)
  • Exhibit 63: Data Table on Vitamin K antagonists - Year-over-year growth 2022-2027 (%)
  • 7.7 Market opportunity by Type
  • Exhibit 64: Market opportunity by Type ($ million)
  • Exhibit 65: Data Table on Market opportunity by Type ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 67: Chart on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibit 68: Data Table on Market share By Geographical Landscape 2022-2027 (%)
  • 9.2 Geographic comparison
  • Exhibit 69: Chart on Geographic comparison
  • Exhibit 70: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2022-2027
  • Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • 9.4 Europe - Market size and forecast 2022-2027
  • Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • 9.5 Asia - Market size and forecast 2022-2027
  • Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
  • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • 9.7 US - Market size and forecast 2022-2027
  • Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
  • 9.8 Germany - Market size and forecast 2022-2027
  • Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • 9.9 UK - Market size and forecast 2022-2027
  • Exhibit 95: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 96: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 97: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibit 98: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • 9.10 Japan - Market size and forecast 2022-2027
  • Exhibit 99: Chart on Japan - Market size and forecast 2022-2027 ($ million)
  • Exhibit 100: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
  • Exhibit 101: Chart on Japan - Year-over-year growth 2022-2027 (%)
  • Exhibit 102: Data Table on Japan - Year-over-year growth 2022-2027 (%)
  • 9.11 Canada - Market size and forecast 2022-2027
  • Exhibit 103: Chart on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 104: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 105: Chart on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibit 106: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity By Geographical Landscape
  • Exhibit 107: Market opportunity By Geographical Landscape ($ million)
  • Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 109: Impact of drivers and challenges in 2022 and 2027
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 111: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 112: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 113: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 114: Matrix on vendor position and classification
  • 12.3 Abbott Laboratories
  • Exhibit 115: Abbott Laboratories - Overview
  • Exhibit 116: Abbott Laboratories - Business segments
  • Exhibit 117: Abbott Laboratories - Key news
  • Exhibit 118: Abbott Laboratories - Key offerings
  • Exhibit 119: Abbott Laboratories - Segment focus
  • 12.4 Aspen Pharmacare Holdings Ltd
  • Exhibit 120: Aspen Pharmacare Holdings Ltd - Overview
  • Exhibit 121: Aspen Pharmacare Holdings Ltd - Business segments
  • Exhibit 122: Aspen Pharmacare Holdings Ltd - Key offerings
  • Exhibit 123: Aspen Pharmacare Holdings Ltd - Segment focus
  • 12.5 AstraZeneca PLC
  • Exhibit 124: AstraZeneca PLC - Overview
  • Exhibit 125: AstraZeneca PLC - Product / Service
  • Exhibit 126: AstraZeneca PLC - Key news
  • Exhibit 127: AstraZeneca PLC - Key offerings
  • 12.6 Bayer AG
  • Exhibit 128: Bayer AG - Overview
  • Exhibit 129: Bayer AG - Business segments
  • Exhibit 130: Bayer AG - Key news
  • Exhibit 131: Bayer AG - Key offerings
  • Exhibit 132: Bayer AG - Segment focus
  • 12.7 Boehringer Ingelheim International GmbH
  • Exhibit 133: Boehringer Ingelheim International GmbH - Overview
  • Exhibit 134: Boehringer Ingelheim International GmbH - Business segments
  • Exhibit 135: Boehringer Ingelheim International GmbH - Key news
  • Exhibit 136: Boehringer Ingelheim International GmbH - Key offerings
  • Exhibit 137: Boehringer Ingelheim International GmbH - Segment focus
  • 12.8 Bristol Myers Squibb Co.
  • Exhibit 138: Bristol Myers Squibb Co. - Overview
  • Exhibit 139: Bristol Myers Squibb Co. - Product / Service
  • Exhibit 140: Bristol Myers Squibb Co. - Key news
  • Exhibit 141: Bristol Myers Squibb Co. - Key offerings
  • 12.9 Daiichi Sankyo Co. Ltd.
  • Exhibit 142: Daiichi Sankyo Co. Ltd. - Overview
  • Exhibit 143: Daiichi Sankyo Co. Ltd. - Product / Service
  • Exhibit 144: Daiichi Sankyo Co. Ltd. - Key news
  • Exhibit 145: Daiichi Sankyo Co. Ltd. - Key offerings
  • 12.10 Dr Reddys Laboratories Ltd.
  • Exhibit 146: Dr Reddys Laboratories Ltd. - Overview
  • Exhibit 147: Dr Reddys Laboratories Ltd. - Business segments
  • Exhibit 148: Dr Reddys Laboratories Ltd. - Key offerings
  • Exhibit 149: Dr Reddys Laboratories Ltd. - Segment focus
  • 12.11 GlaxoSmithKline Plc
  • Exhibit 150: GlaxoSmithKline Plc - Overview
  • Exhibit 151: GlaxoSmithKline Plc - Business segments
  • Exhibit 152: GlaxoSmithKline Plc - Key news
  • Exhibit 153: GlaxoSmithKline Plc - Key offerings
  • Exhibit 154: GlaxoSmithKline Plc - Segment focus
  • 12.12 Johnson and Johnson Services Inc.
  • Exhibit 155: Johnson and Johnson Services Inc. - Overview
  • Exhibit 156: Johnson and Johnson Services Inc. - Business segments
  • Exhibit 157: Johnson and Johnson Services Inc. - Key news
  • Exhibit 158: Johnson and Johnson Services Inc. - Key offerings
  • Exhibit 159: Johnson and Johnson Services Inc. - Segment focus
  • 12.13 LEO Pharma AS
  • Exhibit 160: LEO Pharma AS - Overview
  • Exhibit 161: LEO Pharma AS - Business segments
  • Exhibit 162: LEO Pharma AS - Key offerings
  • Exhibit 163: LEO Pharma AS - Segment focus
  • 12.14 Novartis AG
  • Exhibit 164: Novartis AG - Overview
  • Exhibit 165: Novartis AG - Business segments
  • Exhibit 166: Novartis AG - Key offerings
  • Exhibit 167: Novartis AG - Segment focus
  • 12.15 Pfizer Inc.
  • Exhibit 168: Pfizer Inc. - Overview
  • Exhibit 169: Pfizer Inc. - Product / Service
  • Exhibit 170: Pfizer Inc. - Key news
  • Exhibit 171: Pfizer Inc. - Key offerings
  • 12.16 Sanofi SA
  • Exhibit 172: Sanofi SA - Overview
  • Exhibit 173: Sanofi SA - Business segments
  • Exhibit 174: Sanofi SA - Key news
  • Exhibit 175: Sanofi SA - Key offerings
  • Exhibit 176: Sanofi SA - Segment focus
  • 12.17 Teva Pharmaceutical Industries Ltd.
  • Exhibit 177: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibit 178: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 179: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibit 180: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 181: Teva Pharmaceutical Industries Ltd. - Segment focus

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 182: Inclusions checklist
  • Exhibit 183: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 184: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 185: Research methodology
  • Exhibit 186: Validation techniques employed for market sizing
  • Exhibit 187: Information sources
  • 13.5 List of abbreviations
  • Exhibit 188: List of abbreviations
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제